艾地骨化醇改善骨质疏松的新靶点—Mini-modeling骨形成

A new target for improving osteoporosis with eldecalcitol—Mini-modeling bone formation

作为抗骨质疏松的基础用药,活性维生素D主要通过促进肠道对钙和磷的吸收,抑制甲状旁腺激素释放,维持血钙和血磷水平正常,进而保证骨骼健康。艾地骨化醇(eldecalcitol,ED-71)是活性维生素D的新型类似物,于2011年正式用于日本骨质疏松患病人群的临床治疗。艾地骨化醇不仅能够促进肠道钙吸收、抑制破骨细胞数量和活性,还可有效促进不依存于破骨细胞骨吸收的局灶性骨形成—"mini-modeling"骨形成,提升骨小梁连续性和增加骨小梁厚度,从而修复骨组织微损伤。

As a basic anti-osteoporosis drug,active vitamin D mainly promotes intestinal absorption of calcium and phosphorus,inhibits the release of parathyroid hormone,and maintains normal blood calcium and phosphorus levels,thus ensuring bone health.Eldecalcitol(ED-71),a novel derivative of active vitamin D,was approved for clinical treatment of osteoporosis in Japan in 2011.Eldecalcitol not only improves intestinal calcium absorption and inhibits osteoclast differentiation,but also effectively promotes"mini-modeling"bone formation-focal bone formation that is independent of osteoclastic bone resorption,elevating trabecular continuity and increasing the thickness of weak trabeculae,thereby repairing the microinjury of bone tissue.